Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Lorenzi

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
Molecular Cancer Therapeutics|August 5, 2020
Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage TrogocytosisSmruthi Vijayaraghavan, Lorraine Lipfert, Kristen Chevalier, et al.
Journal of Dairy Science|March 12, 2023
Staphylococcus aureus adlb gene is associated with high prevalence of intramammary infection in dairy herds of northern Italy: A cross-sectional studyA M Maisano, M Luini, A Gazzola, et al.
Cancer Chemotherapy and Pharmacology|March 17, 2022
Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer modelsNikki DeAngelis, Catherine Ferrante, Gordon Powers, et al.
Molecular Cancer Therapeutics|April 19, 2017
Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor ErdafitinibJayaprakash D Karkera, Gabriela Martinez Cardona, Katherine Bell, et al.
Bioorganic & Medicinal Chemistry Letters|January 3, 2006
Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17beta-hydroxysteroid dehydrogenase type 3Brian E Fink, Ashvinikumar V Gavai, John S Tokarski, et al.
The Prostate|June 1, 2005
Identification of novel functional inhibitors of 17beta-hydroxysteroid dehydrogenase type III (17beta-HSD3)Thomas E Spires, Brian E Fink, Ellen K Kick, et al.
Bioorganic & Medicinal Chemistry Letters|May 8, 2009
Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)Tram Huynh, Zhong Chen, Suhong Pang, et al.
Cell Death and Differentiation|September 17, 2013
Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ERα(+) tumorigenesisS R Chan, C G Rickert, W Vermi, et al.
Molecular Cancer Therapeutics|July 5, 2006
Constitutively active receptor tyrosine kinases as oncogenes in preclinical models for cancer therapeuticsKristen A Kellar, Matthew V Lorenzi, Ching Ping Ho, et al.
Bioorganic & Medicinal Chemistry Letters|December 7, 2007
Identification of 2-amino-5-(thioaryl)thiazoles as inhibitors of nerve growth factor receptor TrkASoong-Hoon Kim, John S Tokarski, Kenneth J Leavitt, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Molecular Cancer Therapeutics|August 5, 2020
Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage TrogocytosisSmruthi Vijayaraghavan, Lorraine Lipfert, Kristen Chevalier, et al.
Journal of Dairy Science|March 12, 2023
Staphylococcus aureus adlb gene is associated with high prevalence of intramammary infection in dairy herds of northern Italy: A cross-sectional studyA M Maisano, M Luini, A Gazzola, et al.
Cancer Chemotherapy and Pharmacology|March 17, 2022
Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer modelsNikki DeAngelis, Catherine Ferrante, Gordon Powers, et al.
Molecular Cancer Therapeutics|April 19, 2017
Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor ErdafitinibJayaprakash D Karkera, Gabriela Martinez Cardona, Katherine Bell, et al.
Bioorganic & Medicinal Chemistry Letters|January 3, 2006
Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17beta-hydroxysteroid dehydrogenase type 3Brian E Fink, Ashvinikumar V Gavai, John S Tokarski, et al.
The Prostate|June 1, 2005
Identification of novel functional inhibitors of 17beta-hydroxysteroid dehydrogenase type III (17beta-HSD3)Thomas E Spires, Brian E Fink, Ellen K Kick, et al.
Bioorganic & Medicinal Chemistry Letters|May 8, 2009
Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)Tram Huynh, Zhong Chen, Suhong Pang, et al.
Cell Death and Differentiation|September 17, 2013
Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ERα(+) tumorigenesisS R Chan, C G Rickert, W Vermi, et al.
Molecular Cancer Therapeutics|July 5, 2006
Constitutively active receptor tyrosine kinases as oncogenes in preclinical models for cancer therapeuticsKristen A Kellar, Matthew V Lorenzi, Ching Ping Ho, et al.
Bioorganic & Medicinal Chemistry Letters|December 7, 2007
Identification of 2-amino-5-(thioaryl)thiazoles as inhibitors of nerve growth factor receptor TrkASoong-Hoon Kim, John S Tokarski, Kenneth J Leavitt, et al.
Pageof 7